ORIC Q2 2023 cash $273.7M, $85M private placement; clinical data milestones set

Oric Pharmaceuticals, Inc.

Cash and investments $273.7M as of June 30, 2023; expected to fund operating plan into late 2025.
Completed $85M private placement with Nextech, EcoR1, Frazier, Venrock, Boxer investors.
Initial Phase 1b data for ORIC-114 at ESMO Oct 20-24, 2023; ORIC-533 data Q4 2023; ORIC-944 data Q1 2024.
R&D expenses $18.8M in Q2 2023 vs $13.8M in Q2 2022, increase due to program advancement and personnel.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Oric Pharmaceuticals, Inc. reported financial results for the fiscal quarter ended June 30, 2023.

Period: the fiscal quarter ended June 30, 2023
Result: reported results

Exact text from the filing

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Oric Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.